Enlarge / Martin Shkreli. (credit: Getty | Drew Angerer )

The pharmaceutical company behind Martin Shkreli's infamous 4,000 percent price hike—now known as Vyera Pharmaceuticals—filed for bankruptcy this week and plans to sell its assets to pay off millions in debts.

In court documents filed Wednesday , Vyera's chief restructuring officer, Lawrence Perkins, largely blamed Shkreli for dooming the company and its affiliates.

"Upon information and belief, Shkreli’s actions have caused serious reputational harm to [the companies] and have hampered [their] ability to, among other things, open certain bank accounts, successfully commercialize new products, and either raise capital or consummate the sale of various [company] assets," Perkins wrote in an affidavit.

Enlarge / Martin Shkreli, former CEO of Turing, smirked his way through a congressional hearing. (credit: CSPAN )

Infamous ex-pharmaceutical executive Martin Shkreli is yet again in trouble with the Federal Trade Commission, which announced today that the convicted fraudster has failed to cooperate with the commission's investigation into whether he violated his lifetime ban from the pharmaceutical industry by starting a company last year called "Druglike, Inc."

In a court filing today, the FTC asked a federal judge in New York to find Shkreli in contempt for failing to turn over requested documents to the FTC and failing to make himself available for an interview. Under the 2022 court order barring him from involvement in the pharmaceutical industry for life, Shkreli is required to provide such information to the FTC, the commission noted.

"Martin Shkreli’s failure to comply with the court’s order demonstrates a clear disregard for the law," Holly Vedova, director of the FTC’s Bureau of Competition, said in a press release. "The FTC will not hesitate to deploy the full scope of its authorities to enable a comprehensive investigation into any potential misconduct."

Enlarge / Martin Shkreli, former CEO of Turing, smirked his way through a congressional hearing. (credit: CSPAN )

Infamous ex-pharmaceutical executive Martin Shkreli has been released from federal prison after serving less than five years of a seven-year sentence for a securities and wire fraud conviction. He is now moving into a US Bureau of Prisons halfway house at an undisclosed location in New York until September 14, 2022.

Shkreli was convicted in August 2017 on two counts of securities fraud and one count of conspiracy to commit securities fraud in connection to what federal prosecutors called a Ponzi-like scheme involving two hedge funds Shkreli managed. In March 2018, a federal judge sentenced him to seven years, which he was serving in minimum security federal prison in Allenwood, Pennsylvania.

His early release—slightly more than four years after his sentencing—reflects time shaved off for good behavior in prison, plus completion of education and rehabilitation programs, according to CNBC . It also includes a credit for the roughly six months he spent in jail prior to his sentencing.